Centene (CNC) Resumen de Acciones
Centene Corporation es una empresa de atención sanitaria gestionada que ofrece programas y servicios a familias con seguro insuficiente y a organizaciones comerciales de Estados Unidos. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 5/6 |
| Crecimiento futuro | 3/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 5/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
CNC Community Fair Values
Create NarrativeSee what 122 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$95.24
FV
32.7% infravalorado descuento intrínseco4.00%
Revenue growth p.a.
20
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
Competidores de Centene Corporation
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$64.14 |
| Máximo en las últimas 52 semanas | US$69.36 |
| Mínimo de 52 semanas | US$28.24 |
| Beta | 1.1 |
| Cambio en 1 mes | -5.10% |
| Variación en 3 meses | 8.45% |
| Cambio de 1 año | 122.63% |
| Variación en 3 años | 0.28% |
| Variación en 5 años | 0.88% |
| Variación desde la OPV | 4,374.88% |
Noticias y actualizaciones recientes
Actualización de narrativa • Aug 11
CNC: Medicaid Margin Recovery Delays Will Eventually Undercut Optimistic Post Q2 Repricing
Analyst models for Centene have reset higher, with the internal fair value estimate moving from about $43.26 to $56.35 as analysts factor in Q2 results, improved Medicaid recovery, and updated P/E assumptions that are broadly reflected in the series of recent price target increases across the Street. Analyst Commentary Street research on Centene over the past several months has leaned constructive, with many firms lifting price targets following Q1 and Q2 updates, adjustments to P/E assumptions, and ongoing debate around Medicaid and exchange margins.Seeking Alpha • Aug 07
Centene: Why Declining Membership Could Actually Be A Bullish Sign
Summary Centene (CNC) is repositioning after a major guidance withdrawal and reputational setback tied to Marketplace morbidity miscalculations. I see CNC intentionally shrinking low-quality Marketplace enrollments and shifting toward higher-margin Medicare Part D, repricing for profitability. Management acknowledges declining membership but frames it as a strategic move to improve business quality and sustainability. CNC’s decisive rate refiling, benefit redesign, and selectivity have produced a narrower, more profitable membership base. Read the full article on Seeking AlphaRecent updates
Actualización de narrativa • Aug 11
CNC: Medicaid Margin Recovery Delays Will Eventually Undercut Optimistic Post Q2 Repricing
Analyst models for Centene have reset higher, with the internal fair value estimate moving from about $43.26 to $56.35 as analysts factor in Q2 results, improved Medicaid recovery, and updated P/E assumptions that are broadly reflected in the series of recent price target increases across the Street. Analyst Commentary Street research on Centene over the past several months has leaned constructive, with many firms lifting price targets following Q1 and Q2 updates, adjustments to P/E assumptions, and ongoing debate around Medicaid and exchange margins.Seeking Alpha • Aug 07
Centene: Why Declining Membership Could Actually Be A Bullish Sign
Summary Centene (CNC) is repositioning after a major guidance withdrawal and reputational setback tied to Marketplace morbidity miscalculations. I see CNC intentionally shrinking low-quality Marketplace enrollments and shifting toward higher-margin Medicare Part D, repricing for profitability. Management acknowledges declining membership but frames it as a strategic move to improve business quality and sustainability. CNC’s decisive rate refiling, benefit redesign, and selectivity have produced a narrower, more profitable membership base. Read the full article on Seeking AlphaActualización de narrativa • Jul 28
CNC: Medicaid Margin Recovery Optimism Will Eventually Prove Overstated Despite Recent Upgrades
Centene's fair value estimate has been updated from $40.00 to about $43.26, as analysts lift price targets across the sector, citing constructive Q2 set ups, improving Medicare Advantage and exchange trends, and a more stable policy backdrop that supports moderate adjustments to revenue growth, profit margin assumptions, and future P/E expectations. Analyst Commentary Recent research on Centene points to a broadly constructive tone, with many firms lifting price targets and highlighting improving trends in Medicare Advantage and exchange businesses.
Actualización de narrativa • Jul 14
CNC: Medicaid Margin Recovery And Cost Actions Will Shape Balanced Earnings Outlook
Centene's analyst price target has been revised higher, with fair value moving from about $61.83 to $63.78 as analysts highlight more supportive exchange trends, early signs of Medicaid margin recovery, and sector wide adjustments that reflect a steadier policy backdrop. Analyst Commentary Recent research on Centene clusters around a more constructive view on earnings power, supported by exchange trends, Medicare Advantage performance, and early signs of Medicaid margin recovery, while still flagging several execution and policy risks that could affect valuation.Actualización de narrativa • Jun 29
CNC: Medicaid Margin Recovery And Cost Actions Will Support Balanced Outlook
Centene's analyst fair value estimate has moved from about $54.94 to roughly $61.83 as analysts factor in Medicaid margin recovery, a more stable policy backdrop for managed care, and updated earnings models that reflect recent Q1 trends and revised sector price targets. Analyst Commentary Recent research on Centene clusters around two themes: improving confidence in Medicaid and Marketplace margins, and a debate over how much of that recovery is already reflected in the stock's valuation.Artículo de análisis • Jun 19
Centene (CNC) Stock Could Be 11% Overvalued After Employee Buyout Offer
Centene (CNC) stock is in focus after the company moved to offer voluntary buyouts to most employees, a cost reduction step tied to weaker health plan membership, especially in Affordable Care Act marketplace products. See our latest analysis for Centene. Despite the recent buyout announcement and a sharp pullback of nearly 4% on the day it was reported, Centene’s share price has a 90 day share price return of 77.38% and a 1 year total shareholder return of 10.64%. However, 3 and 5 year total...
Actualización de narrativa • Jun 15
CNC: Medicaid Margin Recovery And Stable Policy Backdrop Will Support Future Earnings
Centene's analyst fair value estimate has been updated from $60.51 to $80.00. This reflects a broad series of higher Street price targets as analysts highlight a more stable managed care policy backdrop, margin recovery potential, and evidence of muted medical cost trends and softer utilization across the sector.Actualización de narrativa • Jun 01
CNC: Medicaid Margin Recovery Expectations Will Eventually Disappoint Current Optimism
Narrative Update Overview The analyst fair value estimate for Centene has moved from $32.00 to $40.00 as analysts factor in improving margin recovery expectations across government programs, steadier commercial trends, and a modestly higher assumed future P/E multiple that aligns with a series of recent price target increases across the Street. Analyst Commentary Recent Street research on Centene has shifted toward a more constructive stance, with multiple firms lifting price targets and, in some cases, upgrading ratings.Actualización de narrativa • May 16
CNC: Margin Recovery Efforts Will Offset Policy And Exchange Uncertainty
Centene's updated analyst price target moves from $43.47 to $54.94 as analysts factor in slightly higher revenue growth assumptions, a higher forward P/E multiple, and recent price target increases and upgrades across several research firms, balanced by some ongoing margin concerns. Analyst Commentary Recent research updates on Centene show a mix of optimism on the earnings and margin recovery path alongside caution about Medicaid and exchange exposure.Actualización de narrativa • Apr 29
CNC: Policy And Exchange Uncertainty Will Pressure Margins And Constrain Upside
Analysts have trimmed the fair value estimate for Centene to $43.47 from $44.18, reflecting updated views on revenue growth, margin potential, and a lower expected future P/E multiple, even as several recent price target revisions highlight ongoing debate around the stock. Analyst Commentary Recent Street research paints a mixed picture for Centene, with several firms adjusting price targets and ratings as they reassess the company after Q4 results, updated guidance, and regulatory developments.Actualización de narrativa • Apr 15
CNC: Medicaid Margins In 2026 Will Underpin Future Earnings Power
Centene's updated analyst price targets show only a modest reduction in implied fair value to about $60.51, as analysts factor in slightly better revenue growth and margins while tempering expectations with lower assumed P/E multiples and continued concern about margin pressure and exchange and Medicaid visibility. Analyst Commentary Recent research on Centene points to a mixed backdrop, but with a clear group of bullish analysts highlighting valuation support, execution on margins, and potential growth from policy and rate decisions.Actualización de narrativa • Apr 01
CNC: Government Program Margins In 2026 Will Support Future Earnings Power
Centene's updated analyst price targets show a modest downward reset of about $4 across several firms to a range of roughly $32 to $49, with analysts citing recalibrated valuation multiples, ongoing Medicaid and exchange visibility questions, and mixed readthroughs from recent Q4 results and policy headlines. Analyst Commentary Recent research shows a split view on Centene, with some firms trimming targets and others lifting them, but the common thread is a focus on how Medicaid, exchange membership, and Q4 execution shape the risk and reward profile from here.Actualización de narrativa • Mar 18
CNC: Government Managed Care Recovery In 2026 Will Support Future Earnings Power
Narrative Update Centene's implied fair value estimate has edged lower to about $60.89 from $62.81 as analysts recalibrated price targets. This reflects slightly softer growth and margin assumptions and a mix of recent target cuts and trims in valuation multiples across the group.Actualización de narrativa • Mar 04
CNC: Medicaid And Exchange Uncertainty Will Pressure Margins Despite 2026 EPS Guidance
Analysts have nudged their average price targets for Centene higher into a $43 to $59 range, pointing to margin improvement efforts, potential earnings power across segments, and sector recovery themes, even as they flag ongoing uncertainty around Medicaid and exchange visibility. Analyst Commentary Recent research on Centene shows a mix of optimism around margin potential and earnings power, alongside pointed concerns about execution risks in key government programs.Actualización de narrativa • Feb 17
CNC: Policy Uncertainty And Margin Recovery Prospects Will Shape Balanced Outlook
Analysts have lifted their average price target on Centene by about $3 to roughly $44, citing updated views on fair value, slightly higher expected profit margins and P/E, and ongoing research that points to potential margin recovery in government managed care despite recent CMS related concerns. Analyst Commentary Recent research on Centene reflects a mix of optimism around long term earnings power in government managed care and caution around policy and utilization risks that could affect how quickly that potential is realized.Actualización de narrativa • Feb 03
CNC: CMS Rate Pressure And Medicaid Uncertainty Will Restrain Future Earnings Recovery
Analysts have lifted their price targets on Centene into a US$43 to US$59 range, citing updated views on government managed care earnings potential and recently softer utilization trends, even as broader commentary highlights ongoing policy and Medicaid uncertainty for the sector. Analyst Commentary Recent research on Centene sits against a mixed backdrop for government managed care, with several firms highlighting both potential earnings recovery drivers and ongoing policy and contract risks.Actualización de narrativa • Jan 20
CNC: Government Managed Care Policy Tailwinds Will Support Future Earnings Power
Analysts have lifted their fair value estimate for Centene from about $54.65 to roughly $62.81, citing updated views on discount rates, revenue growth, margins, and future P/E following recent price target hikes and sector commentary around government managed care and the "Great Healthcare Plan." Analyst Commentary Bullish analysts are highlighting a mix of policy tailwinds, product positioning, and company specific execution as reasons to revisit Centene's valuation. Recent research focuses on how government managed care, Medicare Advantage rate discussions, and the "Great Healthcare Plan" could influence earnings power and the multiple investors are willing to pay.Actualización de narrativa • Jan 06
CNC: Marketplace Margin Recovery And Medicaid Pressures Will Shape Balanced Outlook
Analysts have raised their implied fair value estimate for Centene to about US$41 from roughly US$40, reflecting a mix of higher price targets tied to recent earnings beats and margin recovery expectations in Marketplace and Medicaid, partially balanced by concerns around Medicaid trends and contract losses. Analyst Commentary Recent Street research on Centene reflects a split view, with some analysts focusing on earnings power from margin recovery and others highlighting ongoing risks in Medicaid and selected contracts.Actualización de narrativa • Dec 19
CNC: Medicaid Margin Pressures Will Likely Cap Earnings Recovery Ahead
Analysts have raised their fair value estimate for Centene to $32 from $24, citing improving margin visibility, stronger than expected Q3 results, and a more constructive long term earnings trajectory despite near term Medicaid and contract headwinds. Analyst Commentary Street research following Centene's Q3 earnings has been mixed, with several firms lifting price targets on the back of stronger profitability trends while others caution that EPS visibility remains constrained by Medicaid and Marketplace uncertainties.Actualización de narrativa • Dec 05
CNC: Marketplace And Medicaid Margin Normalization Will Offset Policy And Contract Headwinds
Analysts have modestly raised their price target on Centene to $39.94 from $39.41, citing improved profit margin visibility and expectations for continued EPS growth as Marketplace and Medicaid margins recover, despite lingering near-term Medicaid pressures. Analyst Commentary Street research on Centene has become more polarized, with several bullish analysts lifting price targets into the mid 40s on the back of Q3 outperformance and clearer earnings visibility, while a cohort of more cautious voices highlight lingering Medicaid and Star rating risks that could constrain valuation multiple expansion.Actualización de narrativa • Nov 21
CNC: Margin Recovery In Medicaid And Marketplace Will Drive 2026 Earnings Upside
Centene's analyst price target has increased by $5.59 to $45.00, as analysts expect margin recovery in the Marketplace and Medicaid segments to drive accelerated earnings growth, despite ongoing near-term pressures. Analyst Commentary Recent research coverage of Centene highlights a mix of positive and negative outlooks, with analyst views divided over the company’s near- and medium-term trajectory.Actualización de narrativa • Nov 06
CNC: Medicaid Margin Stability And 26% ACA Premium Hike Will Shape 2026 Prospects
Centene’s analyst price target has been raised from $36 to approximately $39.76 per share. Analysts cite improving Medicaid profitability and stronger earnings guidance as key drivers for the upward revision.Actualización de narrativa • Oct 22
Analysts Lift Centene Price Target on Margin Recovery but Warn of Lasting Sector Headwinds
Centene's analyst fair value target has been increased from $34.63 to $36.00. Analysts highlight improving margin visibility and constructive EPS guidance updates as key factors supporting the upward revision.Actualización de narrativa • Oct 08
Medicaid And Medicare Advantage Will Expand Health Care Access
Centene's analyst price target increased from $33.94 to $34.63, as analysts cited stable EPS guidance, anticipated Medicaid margin improvement, and a constructive outlook for Marketplace rates as supporting factors for the revision. Analyst Commentary Recent analyst research on Centene reflects a full spectrum of perspectives, as experts weigh strong execution signals against ongoing uncertainties in the managed care and healthcare exchange landscape.Actualización de narrativa • Sep 19
Medicaid And Medicare Advantage Will Expand Health Care Access
Centene's modest price target increase reflects mixed analyst sentiment, with optimism around reaffirmed FY25 EPS guidance and Medicaid margin improvements tempered by concerns over ongoing Medicaid and marketplace pressures, regulatory risks, and reduced long-term earnings visibility, resulting in a slight upward revision of fair value to $33.94. Analyst Commentary Bullish analysts cite reaffirmation of FY25 adjusted EPS guidance and constructive commentary on Medicaid margin improvement, ACA Marketplace rate refiling, and Stars performance as supporting recent price target raises.Artículo de análisis • Sep 12
Centene Corporation's (NYSE:CNC) Price Is Right But Growth Is Lacking After Shares Rocket 30%
Centene Corporation ( NYSE:CNC ) shareholders are no doubt pleased to see that the share price has bounced 30% in the...Actualización de narrativa • Sep 04
Medicaid And Medicare Advantage Will Expand Health Care Access
Centene’s analyst price target remains at $34.56 as ongoing macro and regulatory uncertainty, elevated Medicaid cost trends, and withdrawn 2025 EPS guidance have driven increased caution and reduced forward earnings visibility. Analyst Commentary Persistent macro uncertainty and regulatory volatility in the healthcare exchange (ACA Marketplace) and Medicaid markets are driving cautious outlooks, especially due to potential disenrollment, risk pool degradation, and rate/trend volatility stemming from legislative changes and the expiration of enhanced APTCs. Centene’s withdrawal of FY2025 EPS guidance, prompted by incorrect Marketplace risk-adjustment assumptions and elevated Medicaid cost trends, has resulted in significant downward revisions to earnings estimates for the next three years.Seeking Alpha • Mar 26
Centene: A Leader In Government-Sponsored Insurance And Its Prospects
Summary Centene's business transformation and strategic focus on core segments have led to increased operational marginality, despite losing 3.3 million Medicaid customers in 2024. I assign a "Buy" rating to Centene, with a fair valuation of $73 per share, indicating a 27% potential increase from the current price. The company’s competitive advantage lies in its focus on Medicaid and Medicare, but it faces risks from regulatory changes and strong competition. Centene's prospects are bolstered by demographic trends, Medicaid privatization, and ACA Marketplace demand, with expected improvements in cash flow and profitability. Read the full article on Seeking AlphaSeeking Alpha • Mar 18
Centene Corporation Is Resilient And Will Thrive
Summary Centene Corporation is a buy opportunity under $60, with a strong valuation and momentum, despite market volatility and economic concerns. The company reported strong Q4 '24 results, with EPS of $0.80 and FY '24 EPS of $7.17, and management raised 2025 revenue guidance by $4 billion. Risks include potential Medicaid and Medicare enrollment cuts, program pullbacks, and cash flow concerns for the company, but we expect management to navigate these challenges. Insiders and hedge funds are investing, indicating confidence in Centene's resilience and growth potential, with a target price of around $72. Read the full article on Seeking AlphaSeeking Alpha • Jan 02
Centene: Attractive Risk-Reward For A Growing Company At A Value Price
Summary Centene reported strong Q3’24 results, beating revenue expectations by $4.13 billion and achieving EPS of $1.62, driven by Medicaid rate increases and membership growth. Key highlights from the quarter include successful Medicaid reprocurements, improved 2025 Medicare Advantage star ratings, and advancements in AI for operational efficiency, positioning Centene for long-term growth. Despite some leverage, Centene's investment-grade rating and attractive debt maturities suggest financial stability, with a promising outlook for EPS growth and Medicare revenue. Insider buying and undervaluation, with Centene trading at around 10x earnings, indicate confidence in the company's future despite Medicaid redetermination and regulatory risks. Read the full article on Seeking AlphaRentabilidad de los accionistas
| CNC | US Healthcare | Mercado US | |
|---|---|---|---|
| 7D | -2.9% | -1.5% | -2.1% |
| 1Y | 122.6% | 23.0% | 18.8% |
Rentabilidad vs. Industria: CNC superó a la industria US Healthcare, que obtuvo un rendimiento del 23% el año pasado.
Rentabilidad vs. Mercado: CNC superó al mercado US, que obtuvo un rendimiento del 18.8% el año pasado.
Volatilidad de los precios
| CNC volatility | |
|---|---|
| CNC Average Weekly Movement | 5.8% |
| Healthcare Industry Average Movement | 7.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Precio estable de las acciones: CNC no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de CNC (6%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1984 | 61,100 | Sarah London | www.centene.com |
Centene Corporation es una empresa de atención sanitaria gestionada que ofrece programas y servicios a familias con seguro insuficiente y a organizaciones comerciales en Estados Unidos. Opera a través de cuatro segmentos: Medicaid, Medicare, Comercial y Otros. El segmento de Medicaid ofrece los programas de asistencia temporal a familias necesitadas; ampliación de Medicaid; personas mayores, ciegas o discapacitadas; y seguro médico infantil, así como servicios y apoyos a largo plazo; acogimiento familiar; y planes de Medicaid-Medicare.
Resumen de fundamentos de Centene Corporation
| Estadísticas fundamentales de CNC | |
|---|---|
| Capitalización bursátil | US$31.96b |
| Beneficios(TTM) | -US$5.10b |
| Ingresos (TTM) | US$180.30b |
0.2x
Ratio precio-ventas (PS)-6.2x
Ratio precio-beneficio (PE)¿Está CNC sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de CNC | |
|---|---|
| Ingresos | US$180.30b |
| Coste de los ingresos | US$159.72b |
| Beneficio bruto | US$20.58b |
| Otros gastos | US$25.68b |
| Beneficios | -US$5.10b |
Últimos beneficios comunicados
Jun 30, 2026
Próxima fecha de beneficios
Oct 27, 2026
| Beneficios por acción (BPA) | -10.32 |
| Margen bruto | 11.41% |
| Margen de beneficio neto | -2.83% |
| Ratio deuda/patrimonio | 71.1% |
¿Cómo se ha desempeñado CNC a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/08/20 07:56 |
| Precio de las acciones al final del día | 2026/08/20 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Centene Corporation está cubierta por 33 analistas. 14 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| null null | Argus Research Company |
| Hua Ha | Baird |
| Andrew Mok | Barclays |